Starling Oncology (STLNW) Debt Ratio (2020 - 2026)

Starling Oncology (STLNW) has reported Debt Ratio for 7 consecutive years, with 0.45 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio fell 4.55% year-over-year to 0.45; the trailing twelve-month figure through Jun 2026 stood at 0.45 (down 4.55% YoY), and the FY2025 full-year result was 0.47, down 12.82% from the prior year.
• Debt Ratio slipped to 0.45 in Q2 2026 per STLNW's latest filing, from 0.47 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.54 in Q4 2024 and bottomed at 0.28 in Q3 2022.
• Historically, Debt Ratio has averaged 0.43 across 5 years, with a median of 0.45 in 2025.
• The sharpest annual moves came in 2022 and 2025: Debt Ratio surged 34151.98% in 2022, then declined 12.82% in 2025.
• Over 5 years, Debt Ratio stood at 0.31 in 2022, then soared by 34.68% to 0.41 in 2023, then advanced by 29.94% to 0.54 in 2024, then slipped by 12.82% to 0.47 in 2025, then retreated by 4.67% to 0.45 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.45, 0.47, and 0.47 for Q2 2026, Q1 2026, and Q4 2025 respectively.